Access the full text.
Sign up today, get DeepDyve free for 14 days.
(2002)
Optimized virological response in genotype 4 chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) (pegasys) in combination with ribavirin
T. Asselah, P. Marcellin (2011)
New direct‐acting antivirals' combination for the treatment of chronic hepatitis CLiver International, 31
F. Hasan, H. Asker, Jameela al-Khaldi, I. Siddique, Misfer Al-Ajmi, Salim Owaid, R. Varghese, B. al-Nakib (2004)
Peginterferon Alfa-2b Plus Ribavirin for the Treatment of Chronic Hepatitis C Genotype 4American Journal of Gastroenterology, 99
Mahmoud Khattab, P. Ferenci, S. Hadziyannis, M. Colombo, M. Manns, P. Almasio, R. Esteban, A. Abdo, S. Harrison, Nazir Ibrahim, P. Cacoub, M. Eslam, Samuel Lee (2011)
Management of hepatitis C virus genotype 4: recommendations of an international expert panel.Journal of hepatology, 54 6
A. Sánchez-Quijano, M. Abad, R. Torronteras, C. Rey, J. Pineda, M. Leal, J. Macías, E. Lissen (1997)
Unexpected high prevalence of hepatitis C virus genotype 4 in Southern Spain.Journal of hepatology, 27 1
T. Asselah, S. Muynck, P. Broët, J. Masliah-Planchon, Maud Blanluet, I. Bièche, M. Lapalus, M. Martinot‐Peignoux, O. Lada, E. Estrabaud, Qian Zhang, Ahmed Ray, D. Vidaud, M. Ripault, N. Boyer, P. Bedossa, D. Valla, M. Vidaud, P. Marcellin (2012)
IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C.Journal of hepatology, 56 3
J. McHutchison, G. Everson, S. Gordon, I. Jacobson, M. Sulkowski, R. Kauffman, L. Mcnair, J. Alam, A. Muir (2009)
Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection.The New England journal of medicine, 360 18
Remy Aj, É. Verdier, P. Perney, J. Ducos, P. Blanc, François Blanc, D. Larrey (1998)
Route of infection, liver histology and response to interferon in patients with chronic hepatitis caused by genotype 4 HCV infection in a Western country.Journal of hepatology, 29 1
F. Al-Faleh, Q. Hadad, M. Khuroo, A. Aljumah, A. Algamedi, H. Al-Ashgar, M. Al-Ahdal, I. Mayet, M. Khan, G. Kessie (2004)
Peginterferon α‐2b plus ribavirin compared with interferon α‐2b plus ribavirin for initial treatment of chronic hepatitis C in Saudi patients commonly infected with genotype 4Liver International, 24
F. Mcomish, P. Yap, B. Dow, E. Follett, Clive Seed, Anthony Keller, T. Cobain, T. Krusius, E. Kolho, R. Naukkarinen (1994)
Geographical distribution of hepatitis C virus genotypes in blood donors: an international collaborative surveyJournal of Clinical Microbiology, 32
(2002)
NIH Consensus Statement on Management of Hepatitis C: 2002.NIH consensus and state-of-the-science statements, 19 3
P. Ferenci, T. Scherzer, H. Kerschner, K. Rutter, S. Beinhardt, H. Hofer, M. Schöniger-Hekele, H. Holzmann, P. Steindl‐Munda (2008)
Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy.Gastroenterology, 135 5
A NS5A replication complex inhibitor, combined with PEG-Interferon-Alpha-2A and ribavirin in treatment-naïve HCV-Genotype 1 or 4 subjects: The phase 2B momentum study week 12 results
J. McHutchison, Michael Manns, A. Muir, N. Terrault, I. Jacobson, N. Afdhal, E. Heathcote, S. Zeuzem, H. Reesink, Jyotsna Garg, M. Bsharat, S. George, R. Kauffman, N. Adda, Adrian M.D. (2010)
Telaprevir for previously treated chronic HCV infection.The New England journal of medicine, 362 14
B. Bacon, M. Shiffman, Flavia Mendes, R. Ghalib, T. Hassanein, G. Morelli, Shobha Joshi, K. Rothstein, P. Kwo, N. Gitlin (2009)
Retreating chronic hepatitis C with daily interferon alfacon‐1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT resultsHepatology, 49
(2011)
HCV NS5A Inhibitors Modulate Multiple Aspects of NS5A Expression
O. Shobokshi, F. Serebour, L. Skakni, Yassin Al‐Saffy, Mohammad Ahdal (1999)
Hepatitis C genotypes and subtypes in Saudi ArabiaJournal of Medical Virology, 58
Jensen Jensen, Wedemeyer Wedemeyer, Herring Herring (2010)
High rates of early viral response, promising safety profile and lack of resistance related breakthrough in HCV GT 1/4 patients treated with RG7128 plus PegIFN alfa‐2a (40KD)/RBV: Planned Week 12interim analysis from the PROPEL studyHepatology, 52
(2002)
Treatment with PEG-interferon alfa-2b (PEG-IFN) plus ribavirin compared to interferon alfa-2b (IFN alfa-2b)plus ribavirin on subjects with chronic hepatitis C infected with HCV genotype
(2007)
Sustained virologic response with albinterferon alfa-2b plus ribavirin treatment in prior interferon therapy nonresponders
O. Shobokshi, F. Serebour, L. Skakni, N. Al-Jasser, A. Tantawi, A. Sabah, T. Dinish, M. Al-Quaiz, K. Qahtani, A. Sandokji (2003)
996 Combination therapy of peginterferon alfa-2A (40KD) (PEGASYS(R)) and ribavirin (COPEGUS(R)) significantly enhance sustained virological and biochemical response rate in chronic hepatitis C genotype 4 patients in Saudi ArabiaHepatology, 38
A. Koshy, J. Madda, P. Marcellin, M. Martinot (2002)
Treatment of Hepatitis C Virus Genotype 4–Related Cirrhosis: Ribavirin and Interferon Combination Compared With Interferon AloneJournal of Clinical Gastroenterology, 35
Dosage and Efficacy of a Novel Y shaped molecule of Pegylated Interferon alpha 2a for Treatment of Chronic HCV
S. Kamal (2011)
Hepatitis C virus genotype 4 therapy: progress and challengesLiver International, 31
G. Matera, A. Lamberti, A. Quirino, D. Focà, A. Giancotti, G. Barreca, V. Guadagnino, M. Liberto (2002)
Changes in the prevalence of hepatitis C virus (HCV) genotype 4 in Calabria, Southern Italy.Diagnostic microbiology and infectious disease, 42 3
Dike Qiu, J. Lemm, D. O'Boyle, Jin‐Hua Sun, P. Nower, V. Nguyen, L. Hamann, L. Snyder, D. Deon, E. Ruediger, N. Meanwell, M. Belema, M. Gao, R. Fridell (2011)
The effects of NS5A inhibitors on NS5A phosphorylation, polyprotein processing and localization.The Journal of general virology, 92 Pt 11
R. Flisiak, S. Feinman, M. Jabłkowski, A. Horban, W. Kryczka, M. Pawłowska, J. Heathcote, G. Mazzella, C. Vandelli, V. Nicolas‐Métral, P. Grosgurin, J. Liz, P. Scalfaro, H. Porchet, R. Crabbé (2009)
The cyclophilin inhibitor Debio 025 combined with PEG IFNα2a significantly reduces viral load in treatment‐naïve hepatitis C patientsHepatology, 49
Y. Benhamou, J. Moussalli, V. Ratziu, P. Lebray, V. Gysen, K. Backer, A. Ghys, R. Heeswijk, T. Vangeneugden, G. Picchio, M. Beumont‐Mauviel (2009)
10 RESULTS OF A PROOF OF CONCEPT STUDY (C210) OF TELAPREVIR MONOTHERAPY AND IN COMBINATION WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE 4 HCV PATIENTSJournal of Hepatology, 50
A. Oni, T. Harrison (1996)
Genotypes of hepatitis C virus in NigeriaJournal of Medical Virology, 49
M. Manns, G. Foster, J. Rockstroh, S. Zeuzem, F. Zoulim, M. Houghton (2008)
The way forward in HCV treatment — finding the right pathNature Reviews Drug Discovery, 7
S. Seiwert, S. Andrews, Yutong Jiang, V. Serebryany, Hua Tan, K. Kossen, P. Rajagopalan, S. Misialek, S. Stevens, A. Stoycheva, Jin Hong, Sharlene Lim, X. Qin, R. Rieger, K. Condroski, Hailong Zhang, M. Do, C. Lemieux, G. Hingorani, D. Hartley, J. Josey, Lin Pan, L. Beigelman, L. Blatt (2008)
Preclinical Characteristics of the Hepatitis C Virus NS3/4A Protease Inhibitor ITMN-191 (R7227)Antimicrobial Agents and Chemotherapy, 52
S. Ray, R. Arthur, Anthony Carella, J. Bukh, David Thomas (2000)
Genetic epidemiology of hepatitis C virus throughout egypt.The Journal of infectious diseases, 182 3
(2012)
Combination therapy of peginterferon alfa-2a (40KD) (PEGASYS) and Liver International
Jean–François Rossignol, S. Kabil, Y. el-Gohary, A. Elfert, E. Keeffe (2008)
Clinical trial: randomized, double‐blind, placebo‐controlled study of nitazoxanide monotherapy for the treatment of patients with chronic hepatitis C genotype 4Alimentary Pharmacology & Therapeutics, 28
O. Weiland, M. Fried, S. Hadziyannis, G. Foster, D. Messinger, K. Freivogel, M. Chaneac (2004)
522 Combination therapy with peginterferon alfa-2A (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) in treatment-naive patients with chronic hepatitis C and genotype 1 infection: Individual estimated probability of sustained virological response (SVR)Journal of Hepatology, 40
F. Al-Faleh, S. Huraib, F. Sbeih, M. Al-Karawi, R. Al-Rashed, I. Al-Mofleh, M. Sougiyyah, M. Shaheen, S. Ramia (1995)
Hepatitis C virus genotypes in patients with chronic liver disease and haemodialysis patients from Saudi ArabiaJournal of Viral Hepatitis, 2
C. Fretz, D. Jeannel, L. Stuyver, V. Hervé, F. Lunel, A. Boudifa, C. Mathiot, G. Thé, J. Fournel (1995)
HCV infection in a rural population of the Central African republic (CAR): Evidence for three additional subtypes of genotype 4Journal of Medical Virology, 47
J. Dienstag, J. McHutchison (2006)
American Gastroenterological Association medical position statement on the management of hepatitis C.Gastroenterology, 130 1
H. Yee, S. Currie, K. Tortorice, M. Cozen, Hui Shen, Summer Chapman, F. Cunningham, A. Monto (2011)
Retreatment of Hepatitis C with Consensus Interferon and Ribavirin After Nonresponse or Relapse to Pegylated Interferon and Ribavirin: A National VA Clinical Practice StudyDigestive Diseases and Sciences, 56
S. Beinhardt, S. Rasoul-rockenschaub, T. Scherzer, P. Ferenci (2011)
Silibinin monotherapy prevents graft infection after orthotopic liver transplantation in a patient with chronic hepatitis C.Journal of hepatology, 54 3
M. Elazar, Michael Liu, S. McKenna, Ping Liu, Elizabeth Gehrig, J. Puglisi, J. Rossignol, J. Glenn (2009)
The anti-hepatitis C agent nitazoxanide induces phosphorylation of eukaryotic initiation factor 2alpha via protein kinase activated by double-stranded RNA activation.Gastroenterology, 137 5
I. Mederacke, H. Wedemeyer (2009)
Nitazoxanide for the treatment of chronic hepatitis C new opportunities but new challenges?Annals of hepatology, 8 2
J. Hoofnagle (2002)
Course and outcome of hepatitis CHepatology, 36
Abstract Hepatitis C virus genotype 4 (HCV‐4) is the most common type of hepatitis C virus (HCV) in the Middle East and Africa, in particular Egypt. Since the development of new protease inhibitors, the response of HCV‐4 to the standard regimen of treatment (pegylated interferon/ribavirin) lags behind other genotypes and has become the most resistant type to treat. The development of therapeutic strategies for all patients with HCV‐4 whether they are naïve, have experienced a virological breakthrough, are relapsers or non‐responders is still a considerable challenge. New types of interferon (Consensus Interferon, Y‐shaped, Albinterferon…) and new direct action antiviral drugs (Nitazoxanide, Vit.D, other) may improve the treatment of patients with HCV‐4. The IL28B CC polymorphism may be associated with sustained virological response.
Liver International – Wiley
Published: Feb 1, 2012
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.